Everfront Biotech Inc.- Rising Star in Pharmaceutical Innovation
Everfront Biotech Participate BIO ASIA-Taiwan 2023 Exihibition.
Welcome to Our Booth: NSTC INNO ZONE (N814)
- EverFront Biotech Holding Company, a Rising Star in Pharmaceutical Innovation, is in the process of listing on a national exchange, NASDAQ, in the US, to join the world’s biggest market.
- We are also seeking to license our products in China, Japan, Europe, and America.
>> Highlights <<
Product Highlights of Cerebraca® Wafer (👉read more)
- In October 2022, completed enrollment for the Taiwan phase IIa clinical trial
- Cerebraca® Wafer has shown excellent safety and efficacy in its Phase I clinical trial for the treatment of recurrent malignant brain tumors.
- In Phase I clinical trials, Cerebraca® Wafer has demonstrated efficacy without any drug-related adverse reactions.
- The median or average cumulative survival of relapsed malignant brain cancer patients has reached 25-26 months, which is significantly better than existing strategies such as Gliadel® wafer implantation (6.4 months), Temodal capsules (5.8 months), or Avastin injection (9.4 months).
- Cerebraca® Wafer, a breakthrough innovation, synergistically combines the small molecule active pharmaceutical ingredient EF-API-001 with a biodegradable polymer. This unique formulation enables precise and targeted therapeutic effects in cancer treatment by delivering a localized, high concentration of drugs with enhanced permeability, while ensuring sustained release over an extended period of up to one month.
- Key features include effectively inhibiting the growth and metastasis of brain tumor stem cells, maintaining the activity of immune cells to kill tumor cells, overcoming drug resistance to chemotherapy, and enhancing energy in normal cells, thereby improving the quality of life for patients.
